(Q35011885)

5 August 2017

1 reference

title

Therapies directed at vascular endothelial growth factor (English)

1 reference

5 August 2017

0 references

Paul W Manley

1

1 reference

5 August 2017

Georg Martiny-Baron

series ordinal

2

1 reference

5 August 2017

Jean-Marc Schlaeppi

series ordinal

3

1 reference

5 August 2017

Jeanette M Wood

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

1715-1736

1 reference

Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Current biology of VEGF-B and VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Isolation of putative progenitor endothelial cells for angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular progenitors: from biology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Neuropilin is a semaphorin III receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Tumor angiogenesis: past, present and the near future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Expression of vascular endothelial growth factor receptors in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Expression and localization of placenta growth factor and PlGF receptors in human meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Angiogenesis in cancer, vascular, rheumatoid and other disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Angiogenesis and remodeling of airway vasculature in chronic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Human airway smooth muscle cells secrete vascular endothelial growth factor: up-regulation by bradykinin via a protein kinase C and prostanoid-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor enhances atherosclerotic plaque progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Monoclonal antibody strategies to block angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Chemical approaches to the study of protein tyrosine kinases and their implications for mechanism and inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

Relation of neovascularisation to metastasis of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1715

10.1517/13543784.11.12.1715

21 January 2018

Identifiers

DOI

1 reference

release_nrjcuziwnzar5lwzdytv2mh76q

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nrjcuziwnzar5lwzdytv2mh76q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference